Haleon plc (HLN) Stock Analysis

Q: What is the HLN stock price target?

Take-profit $10.28 (+10.5% upside). Prior stop was $8.98.

Q: What are the risks of investing in HLN?

Negative momentum; Below 200-day MA; Momentum score 2.0/10 — below 4.5 minimum.

Q: Is HLN overvalued or undervalued?

Haleon plc trades at a P/E of 18.6 (forward 15.2). TrendMatrix value score: 5.6/10. Overall verdict: Sell.

Q: What do analysts say about HLN?

25 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Momentum 2.0/10 is below the 5.0 floor at $9.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Below 200-day MA.

$9.29+10.5% A.UpsideScore 5.3/10#17 of 29 Drug Manufacturers - Specialty & Generic

Stop $8.98Target $10.28(analyst − 13%)A.R:R 2.1:1

Analyst target$11.81+27.2%5 analysts

$10.28our TP

$9.29price

$11.81mean

$14

Sell if holding. Momentum 2.0/10 is below the 5.0 floor at $9.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Below 200-day MA. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 91d clear, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.

Thesis

Rewards

No bull case signals

Risks

Negative momentum

Below 200-day MA

Key Metrics

P/E (TTM)18.6

P/E (Fwd)15.2

Mkt Cap$41.3B

EV/EBITDA32.9

Profit Mgn15.1%

ROE10.3%

Rev Growth0.6%

Beta0.33

Dividend2.05%

Rating analysts25

Quality Signals

Piotroski F8/9

Options Flow

P/C5.50bearish

IV47%normal

Max Pain$20+115.3% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.615%0.84

Quality6.215%0.93

Growth6.315%0.94

Momentum2.010%0.20

Sentiment6.110%0.61

Insider Activity5.010%0.50

Peer Rank2.910%0.29

Technical Setup7.85%0.39

Risk Profile7.25%0.36

Catalyst5.35%0.27

Overall (Σ contributions)5.33

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.7

Obv

1.0

Ma Position

1.5

Rsi

3.0

Macd

3.7

Capitulation risk (RSI 29, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope flat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

1.5

Quality Rank

4.8

Value Rank

5.5

GatesMomentum 2.0<4.5A.R:R 2.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 91d clearSEMI CYCLE PEAK CLEARSuitability: Moderate

RSI

29 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $9.07Resistance $9.95

Price Targets

$10

A.Upside+10.7%

A.R:R2.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Momentum score 2.0/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-07-30 (91d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is HLN stock a buy right now?

Sell if holding. Momentum 2.0/10 is below the 5.0 floor at $9.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Below 200-day MA. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $8.98. Score 5.3/10, moderate confidence.

What is the HLN stock price target?

Take-profit target: $10.28 (+10.5% upside). Prior stop was $8.98. Stop-loss: $8.98.

What are the risks of investing in HLN?

Negative momentum; Below 200-day MA.

Is HLN overvalued or undervalued?

Haleon plc trades at a P/E of 18.6 (forward 15.2). TrendMatrix value score: 5.6/10. Verdict: Sell.

What do analysts say about HLN?

25 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.

What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.